Mustafa Syed T, Sadat Umar, Majeed Muhammad U, Wong Chih Mun, Michaels Jonathan, Thomas Steve M
Academic Vascular Department, Sheffield University, Sheffield, United Kingdom.
Vascular. 2010 Jan-Feb;18(1):28-33. doi: 10.2310/6670.2010.00003.
Thoracic aortic aneurysms represent a major health problem. Untreated thoracic aortic aneurysms may rupture, which has a dismal outcome. The standard treatment for thoracic aneurysms is open surgical repair, but it is associated with high mortality and morbidity. Endovascular repair provides a less invasive and safer alternative. A systematic review was performed of all published literature on the above subject. Our primary objective was to measure 30-day mortality for nonruptured thoracic aortic aneurysms. Studies describing other pathologies, such as aortic dissection, mycotic aneurysms, penetrating ulcers, traumatic transactions, and pseudoaneurysms, and studies from which independent data for thoracic aortic aneurysm could not be separately extracted were excluded. Case series describing less than 10 patients and all case series describing ruptures or concealed ruptures were excluded as well. Twenty-six case series and one comparative study were identified. This formed a cohort of 1,038 patients. Technical success was possible in more than 97% of patients. The 30-day mortality was calculated to be 5.1% even though the group under study was mostly those who were refused surgery by a surgeon or had a higher surgical risk. The incidence of paraplegia and stroke was 3.1% and 4.7%, respectively. Early endoleak was seen in 16.7% of patients, whereas 11.7% of patients developed late endoleak, but most did not require any additional procedure. The rate of reintervention was 14.9%. The 12-month mortality rate was 14.2%. Endovascular repair shows encouraging short-term results. It is associated with significantly less mortality and morbidity, but long-term results need to be further investigated.
胸主动脉瘤是一个重大的健康问题。未经治疗的胸主动脉瘤可能破裂,后果严重。胸主动脉瘤的标准治疗方法是开放性手术修复,但该方法与高死亡率和高发病率相关。血管内修复提供了一种侵入性较小且更安全的替代方案。我们对所有已发表的关于上述主题的文献进行了系统综述。我们的主要目标是测定未破裂胸主动脉瘤的30天死亡率。排除了描述其他病理情况(如主动脉夹层、霉菌性动脉瘤、穿透性溃疡、创伤性损伤和假性动脉瘤)的研究,以及无法单独提取胸主动脉瘤独立数据的研究。还排除了描述患者少于10例的病例系列以及所有描述破裂或隐匿性破裂的病例系列。共确定了26个病例系列和1项比较研究。这组研究共纳入了1038例患者。超过97%的患者手术成功。尽管所研究的组大多是被外科医生拒绝手术或手术风险较高的患者,但计算得出的30天死亡率为5.1%。截瘫和中风的发生率分别为3.1%和4.7%。16.7%的患者出现早期内漏,而11.7%的患者出现晚期内漏,但大多数患者无需额外手术。再次干预率为14.9%。12个月死亡率为14.2%。血管内修复显示出令人鼓舞的短期结果。它与显著更低的死亡率和发病率相关,但长期结果仍需进一步研究。